LY 2874455

Drug Profile

LY 2874455

Alternative Names: FGF receptor inhibitor - Eli Lilly; LY2874455

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cancer

Most Recent Events

  • 27 Apr 2017 Dana-Farber Cancer Institute and Eli Lilly plan a phase I trial for Acute myeloid leukaemia (Second-line therapy or greater) in USA (NCT03125239)
  • 16 Apr 2016 Adverse events data from a phase I trial in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 01 Feb 2015 Eli Lilly completes a phase I trial in Cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia and South Korea (NCT01212107)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top